Physician profile
Robin E Riddle
NPI 1619346509
$3,312.11
in general payments reported to CMS, 2019-2025
26 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $752 · 2023: $785 · 2024: $959 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.90 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $457.69 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $431.30 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $344.06 | 2022-2025 | Abilify Maintena, Rexulti |
| Otsuka America Pharmaceutical, INC. | $272.99 | 2022-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.66 | 2021-2025 | Caplyta |
| Organogenesis INC. | $231.52 | 2024 | |
| Lilly USA, LLC | $211.55 | 2021-2025 | Mounjaro, Trulicity, Emgality |
| Novo Nordisk INC | $190.54 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $154.93 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.98 | 2021-2025 | Jardiance, Tradjenta |
| Gilead Sciences, INC. | $113.13 | 2023-2025 | |
| Avanir Pharmaceuticals, INC. | $103.22 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $94.31 | 2022-2025 | Ingrezza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.46 | 2024-2025 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $45.68 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $43.82 | 2025 | Veozah |
| Aimmune Therapeutics, INC. | $39.64 | 2025 | Zenpep |
| Dexcom, INC. | $22.60 | 2021 | |
| Boston Scientific Corporation | $21.80 | 2024 | Eluvia |
| Glaxosmithkline, LLC. | $19.50 | 2021 | |
| Axsome Therapeutics, INC. | $18.96 | 2023 | Auvelity |
| Phathom Pharmaceuticals, INC. | $17.94 | 2024 | Voquezna |
| Alkermes, INC. | $17.56 | 2023 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $12.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.36 | 2022 | |
| Organon LLC | $10.54 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Riddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.